背景:该研究旨在研究缺氧诱导因子(HIF)在发育中的作用,programming,和胶质母细胞瘤的治疗潜力。
方法:研究,遵循PRISMA准则,使用MEDLINE(PubMed)系统地检查胶质母细胞瘤中的缺氧和HIF,WebofScience,还有Scopus.共有104项相关研究进行了数据提取。
结果:在104项研究中,全球贡献是多种多样的,中国领先23.1%。产出最高的一年是2019年,占比11.5%。低氧诱导因子1α(HIF1α)经常被研究,其次是缺氧诱导因子2α(HIF2α),骨桥蛋白,和cavolin-1.常见的相关因子和途径包括葡萄糖转运蛋白1(GLUT1)和葡萄糖转运蛋白3(GLUT3)受体,血管内皮生长因子(VEGF),磷酸肌醇3-激酶(PI3K)-Akt-雷帕霉素(mTOR)途径,和活性氧(ROS)。HIF表达与各种胶质母细胞瘤标志相关,包括进展,生存,新生血管形成,葡萄糖代谢,迁移,和入侵。
结论:克服诸如治疗耐药性和缺乏生物标志物的挑战对于将HIF相关疗法有效整合到胶质母细胞瘤的治疗中,以优化患者的预后至关重要。
BACKGROUND: The study aims to investigate the role of hypoxia-inducible factors (HIFs) in the development, progression, and therapeutic potential of glioblastomas.
METHODS: The study, following PRISMA guidelines, systematically examined hypoxia and HIFs in glioblastoma using MEDLINE (PubMed), Web of Science, and Scopus. A total of 104 relevant studies underwent data extraction.
RESULTS: Among the 104 studies, global contributions were diverse, with China leading at 23.1%. The most productive year was 2019, accounting for 11.5%. Hypoxia-inducible factor 1 alpha (HIF1α) was frequently studied, followed by hypoxia-inducible factor 2 alpha (HIF2α), osteopontin, and cavolin-1. Commonly associated factors and pathways include glucose transporter 1 (GLUT1) and glucose transporter 3 (GLUT3) receptors, vascular endothelial growth factor (VEGF), phosphoinositide 3-kinase (PI3K)-Akt-mechanistic target of rapamycin (mTOR) pathway, and reactive oxygen species (ROS). HIF expression correlates with various glioblastoma hallmarks, including progression, survival, neovascularization, glucose metabolism, migration, and invasion.
CONCLUSIONS: Overcoming challenges such as treatment resistance and the absence of biomarkers is critical for the effective integration of HIF-related therapies into the treatment of glioblastoma with the aim of optimizing patient outcomes.